Clearmind Medicine- Kampf gegen Alkohol,Drogen und Übergewicht
eröffnet am 10.01.24 15:34:03 von
neuester Beitrag 27.04.24 20:11:09 von
neuester Beitrag 27.04.24 20:11:09 von
Beiträge: 21
ID: 1.374.981
ID: 1.374.981
Aufrufe heute: 0
Gesamt: 1.346
Gesamt: 1.346
Aktive User: 0
ISIN: CA1850534027 · WKN: A3E2CG · Symbol: CWY0
1,2050
EUR
-5,64 %
-0,0720 EUR
Letzter Kurs 13.05.24 Tradegate
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,5300 | +38,25 | |
| 0,9999 | +31,55 | |
| 0,6230 | +23,86 | |
| 4,9780 | +23,40 | |
| 2,3550 | +20,15 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,1200 | -18,64 | |
| 0,5350 | -20,15 | |
| 3,1700 | -23,06 | |
| 0,9900 | -27,21 | |
| 0,6162 | -56,61 |
Beitrag zu dieser Diskussion schreiben
Feedback
offenbar wohl israel konflikte hier eingepreist...
obwohl in jerusalem ist cmnd wohl sicher,denn da ist bekanntlich nicht nur eine heilige stätte...
obwohl in jerusalem ist cmnd wohl sicher,denn da ist bekanntlich nicht nur eine heilige stätte...
when merger, adi ????
Adi should be fired soon as possible
offerings only to bring market cap over 2,5 mio nasdaq requirement
what silly stupid plan, better off delisting from nasdaq and going to otc
more cash than market cap...
only my opinion
offerings only to bring market cap over 2,5 mio nasdaq requirement
what silly stupid plan, better off delisting from nasdaq and going to otc
more cash than market cap...
only my opinion
leider eine verwässerung, deshalb der rückgang
aber die firma bruacht das geld um die AUD STudie auf den Weg zu bringen
auf clinicaltrials längst terminiert....
strong buy
nur meine meinung
aber die firma bruacht das geld um die AUD STudie auf den Weg zu bringen
auf clinicaltrials längst terminiert....
strong buy
nur meine meinung
rechne persönlich mit merger dieses jahr, mit wem dürfte klar sein
schaun wir mal
nur meine meinung
schaun wir mal
nur meine meinung
Trading Spotlight
10.01.24 3,50 $ 3,57 $ 2,66 $ 2,91 $ 5.121.398 4,71 M $ (quelle nasdaq)
wie können an einem tag 5,1 mio aktien gehandelt werden, wenn nur umgerechnet 3 mio existieren ???
und die meisten davon in festen händen sind.
way oversold here
more shares sold than really exist
nur meine meinung
wie können an einem tag 5,1 mio aktien gehandelt werden, wenn nur umgerechnet 3 mio existieren ???
und die meisten davon in festen händen sind.
way oversold here
more shares sold than really exist
nur meine meinung
schöne zusammenfassung der möglichkeiten
Sehr enge Verknüpfung von CMND und SPRC !!!
SPRC hat vor kurzem fette Finanzierung von 20 Millionen erhalten !!
Man kann spekulieren das auch Clearmind davon irgendwo profitiert !
Lustig auch der letzte Satz:" As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind."
WIe soll das gehen, gemeinsame EInkünfte die gemeinsam genutzt werden ?????
The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of psychedelics with SciSparc's PEA
TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reflects on the successful collaboration in 2023 with Clearmind Medicine Inc. (“Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.
The patent applications are for novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA) and novel proprietary combinations of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, Ketamine, and PEA. PEA is the active ingredient of SciSparc’s proprietary CannAmide™.
The patent applications represent a commitment by SciSparc and Clearmind to offer patients safer and more effective treatments than those available today partly by strengthening their IP portfolios to broaden the therapeutic psychedelic toolbox for patients with mental health disorders that require transformative medicines and by developing treatments that offer synergy, efficacy and safety, while reducing the total cost.
As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
SPRC hat vor kurzem fette Finanzierung von 20 Millionen erhalten !!
Man kann spekulieren das auch Clearmind davon irgendwo profitiert !
Lustig auch der letzte Satz:" As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind."
WIe soll das gehen, gemeinsame EInkünfte die gemeinsam genutzt werden ?????
The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of psychedelics with SciSparc's PEA
TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reflects on the successful collaboration in 2023 with Clearmind Medicine Inc. (“Clearmind") (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems. Early in 2023, Clearmind filed six provisional patent applications with the United States Patent and Trademark Office (USPTO) for unique combinations of future psychedelic-based compounds, as part of its ongoing collaboration with SciSparc.
The patent applications are for novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA) and novel proprietary combinations of 3,4-Methylenedioxymethamphetamine (MDMA), Ibogaine, Ketamine, and PEA. PEA is the active ingredient of SciSparc’s proprietary CannAmide™.
The patent applications represent a commitment by SciSparc and Clearmind to offer patients safer and more effective treatments than those available today partly by strengthening their IP portfolios to broaden the therapeutic psychedelic toolbox for patients with mental health disorders that require transformative medicines and by developing treatments that offer synergy, efficacy and safety, while reducing the total cost.
As part of the collaboration agreement between SciSparc and Clearmind, originally announced on March 8,2022, any assets generated from the collaboration shall be jointly owned by SciSparc and Clearmind.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
quelle chartexchange: cost to borrow so um die 300 %, waren auch schonmal bei 2400 %, wer ist da noch short ???
CMND Borrow Fee (CTB) Latest
At 2024-01-25 10:45:03, there were 95,000 shares available with a fee of 283.97%.
CMND Borrow Fee (CTB) Changes
Updated1 Fee2 % Available Rebate3 %
2024-01-25 10:45:03 283.97 95,000 -278.66
CMND Borrow Fee (CTB) Latest
At 2024-01-25 10:45:03, there were 95,000 shares available with a fee of 283.97%.
CMND Borrow Fee (CTB) Changes
Updated1 Fee2 % Available Rebate3 %
2024-01-25 10:45:03 283.97 95,000 -278.66
die umsätze sind absolut lächerlich hier,
ich gehe davon aus das bereits mehr aktien in festen händen sind als tatsächlich existieren...
aber warum mussten die shortseller das ding auch so nach unten drücken- selber schuld
nur meine private meinung
ich gehe davon aus das bereits mehr aktien in festen händen sind als tatsächlich existieren...
aber warum mussten die shortseller das ding auch so nach unten drücken- selber schuld
nur meine private meinung
Durchsuchen
